Urolithiasis
Conditions
Brief summary
Assess the efficacy and safety of potassium citrate extended-release tablets on Urolithiasis formation or recurrence.
Detailed description
This study takes Rate of stone recurrence as primary outcome measure, by random, blank control, and multicenter clinical trial design method, assess the efficacy and safety of potassium citrate extended-release tablets on Urolithiasis formation or recurrence, provide evidence for drug re-registration, and observe its efficacy on Urinary calculi such as renal tubular acidosis with calcium stone, and uric acid stones with or without calcium stone, urinary tract stone of effectiveness.
Interventions
DRUGPotassium Citrate Extended-release Tablets
Daily 3.24g, Po ,Tid, each 1.08g/tablets
Sponsors
Dawnrays Pharmaceutical (Holdings) Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients with upper urinary tract calculi surgery and/or ESWL within 3 months； * Stone free or had residual stone fragments with a less than 4 mm diamete； * 18-70 years of age; the gender is not limited； * Agree to take effective contraceptive measures during the study period, and female of childbearing age whose pregnancy test is negative； * Subjects with no mental illness and language dysfunction, can understand the situation of the study and have signed informed consent.
Exclusion criteria
* Patients with infectious stones, medical stones and urinary tract obstruction； * Patients with hyperkalemia (K+\>5.5mmol/L) (or patients with factors or disease that can cause hyperkalemia), because the further increase in blood potassium can lead to cardiac arrest. These factors include disease or strenuous exercise, chronic renal failure, uncontrolled diabetes, acute dehydration, excessive, adrenal insufficiency, extensive tissue failure. Patients who takes potassium sparing diuretics (such as triamterene, spironolactone, amiloride)； * Patients with gastrointestinal disorders, such as peptic ulcer, severe vomiting, diarrhea, delayed gastric emptying, intestinal obstruction, etc.； * Combined with cardiovascular, liver, kidney, hematopoietic system, such as severe primary disease, or known to affect the survival of serious diseases (such as cancer or AIDS), or patients with with disabilities mentally or legally； * Patients with renal insufficiency (1.2 times the upper limit of the normal value of serum creatinine and urea nitrogen)； * The recent (within 6 months) with family planners； * Allergic to this product； * To participate in other clinical trials in the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of Urolithiasis recurrence | through study completion, an average of 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Time of stone recurrence | through study completion, an average of 1 year |
| The changes of urine citric acid content compared with baseline | through study completion, an average of 1 year |
| The changes of Urine pH value compared with baseline | through study completion, an average of 1 year |
Countries
China
Contacts
Primary ContactZhangqun YE, M.D.
Outcome results
None listed